BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 19, 2020
View Archived Issues
Bromodomain 2-selective BET inhibitors show antitumor effect in pediatric cancer models
Read More
Medicenna outlines phase III plans for MDNA-55 in recurrent glioblastoma
Read More
NIAID initiates phase I study of SAR-440894
Read More
Avalyn advances phase I/II study of AP-101 in IPF
Read More
Recce receives ethics approval to initiate phase I/II burn wound study of RECCE-327
Read More
CKD-508, second-generation CETP inhibitor with improved safety and efficacy
Read More
Medshine Discovery patents Ret inhibitors
Read More
Neutrophils are literal obstacle to stroke recovery
Read More
Albumin transports proteins across mucosa, into lymph nodes
Read More
Insilico Medicine discloses JAK inhibitors
Read More
Epizyme presents CREBBP and KAT3B inhibitors
Read More
FZD6 as novel biomarker of depression
Read More
Ventyx Biosciences discloses TYK2 ligands
Read More
WHO Solidarity interim results show repurposed antivirals for COVID-19 have little or no effect
Read More
Baylor College of Medicine identifies new antiviral compounds
Read More
TRPA1 channel as a new therapeutic target for chronic post-thoracotomy pain
Read More
New model created for CFTR gene nonsense mutation W1282X cystic fibrosis
Read More
Cellular "pantry" of sorts, lipid droplets double as home security system
Read More
Snai1 inhibition may ameliorate right ventricular failure due to pulmonary hypertension
Read More
Furin inhibitor BOS-318 seems effective for treating cystic fibrosis
Read More
PharmaMar reports data from APLICOV-PC trial with Aplidin in COVID-19
Read More
Agios withdraws MAA for Tibsovo for relapsed or refractory AML with IDH1 mutation
Read More
Orion's OB-002H for prevention of HIV completes first-in-human study
Read More
Aptose begins phase Ia/b study of CG-806 in AML
Read More
FDA clears Mereo to begin phase Ib/II basket study of etigilimab
Read More